For roughly one in three people with depression, the medicine cabinet runs empty before the symptoms do. A small Houston team thinks the next prescription might not be a pill at all, but a device the size of a blueberry tucked against the skull. This year that idea moves from the lab bench toward the operating room.
The implant that never touches the brain
Motif Neurotech's lead product is the DOT, a wireless, battery-free implant about 9 millimeters wide — roughly the size of a blueberry. Surgeons place it in the bone over a targeted brain region during a procedure the company says lasts about 20 minutes, as an outpatient visit. Crucially, the DOT does not penetrate or contact brain tissue. It receives both power and data from an external cap-like device through magnetoelectric transfer, a wireless method developed at Rice University.
The goal is to deliver precise electrical stimulation to circuits that have been clinically linked to mood, then — in a later version — to record brain signals so doctors can see whether the therapy is working. Think of it as a pacemaker for a mood network: implanted once, tuned from outside, no daily pills required.
Why depression is the first target
Motif is aiming first at treatment-resistant depression (TRD) — cases where a person has not improved after trying two or more medications. Clinicians estimate about a third of people with depression fall into this bucket, and existing brain-stimulation options such as transcranial magnetic stimulation can mean weeks of daily clinic visits. Motif's pitch is a one-time, at-home, physician-tunable alternative.
The company was founded in 2022 through the Rice Biotech Launch Pad by Jacob Robinson (now CEO), Kaiyuan Yang, and physicians Sunil Sheth and Sameer Sheth. Its underlying wireless power and stimulation approach came out of Rice University research.
From a university lab to an FDA study
Motif closed an $18.75 million Series A in January 2024, led by Arboretum Ventures with participation from Satori Neuro, Dolby Family Ventures, re.Mind Capital and others, according to the company's announcement carried by Business Wire and Fierce Biotech. In January 2025 the UK's Advanced Research and Invention Agency (ARIA) named Motif for a multimillion-dollar award to develop a therapeutic brain-computer interface; Rice University described the Motif-led "Brain Mesh" project across collaborators at about $5.9 million.
The bigger gate fell in 2026: the U.S. FDA authorized Motif's first clinical trial — an investigational device exemption (IDE) covering the RESONATE early feasibility study. According to coverage in Wired (April 2026) and device tracker BCI Intel, the study is expected to enroll at up to eight leading medical centers, including Baylor College of Medicine, Mass General Brigham, Emory Healthcare, UT Health Houston, the University of Iowa, the University of Utah, NYU and a Houston brain-health practice.
What the first trial will actually test
RESONATE's primary job is safety. Over a 12-month window after implantation, researchers will watch for adverse events and confirm the device and procedure are tolerable. They will also track whether participants show meaningful reductions in depression symptoms on standard clinical scales, plus changes in quality of life, anxiety and cognitive function. This is a first-in-human feasibility step, not a proof that the device treats depression — that bar comes later, with larger pivotal studies.
According to Li An, chief scientist at BrainNet (脑机网), the field's center of gravity is moving "from who can pack the most electrodes into the skull to who can keep a signal stable and a patient safe for years." A depression device that avoids brain tissue entirely fits that shift.
Honest limitations
This article relies on company announcements, trade coverage (MPO, Fierce Biotech, Wired) and a device tracker; it is not based on peer-reviewed clinical results, because none have been published yet. The "one in three" figure for treatment-resistant depression is a widely cited clinical estimate, not a Motif-specific measurement. The RESONATE study's enrollment size and final site list may differ from early reports. No commercial approval exists; the DOT is investigational and not available for sale. I have not evaluated competing depression therapies head-to-head, and long-term safety in humans is simply unknown at this stage.
What readers can do now
- If you or someone you know has not responded to two or more antidepressants, ask a psychiatrist about evidence-based options for treatment-resistant depression, including approved brain-stimulation therapies — and treat any "implant" you read about as experimental until pivotal trials report.
- Follow the RESONATE study on ClinicalTrials.gov (search "Motif" or "RESONATE") rather than relying on press releases for enrollment status and results.
- Be skeptical of anyone offering a "brain pacemaker for mood" commercially today; no such device is approved for depression.
Key takeaways
- Motif Neurotech's DOT is a blueberry-sized, tissue-free implant that received FDA IDE authorization in 2026 to begin its first human depression study.
- The RESONATE trial prioritizes 12-month safety across up to eight U.S. medical centers; efficacy is a later question.
- The bet is minimally invasive bioelectronics for mental health — promising, but still years and several studies away from any clinic.